Fig. 2: Effectiveness outcomes. | Prostate Cancer and Prostatic Diseases

Fig. 2: Effectiveness outcomes.

From: Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study

Fig. 2: Effectiveness outcomes.

Time to mCRPC progression:a A Kaplan–Meier estimates and B adjusted Cox proportional hazards models; MFS: C Kaplan–Meier estimates and D adjusted Cox proportional hazards models. A and C show unadjusted Kaplan–Meier estimates and B and D show Cox proportional hazards models both unadjusted and adjusted for the following baseline characteristics: age group (≤74, 75–84, ≥85 years), race (White, Black/African American, other/unknown), insurance coverage (commercial, public), index year for ARI initiation (2019–2020, 2021–2023), time (months) from nmCRPC diagnosis to index date, baseline PSA groups (<2, 2–< 10, ≥10 ng/mL), baseline PSA doubling time (≤ 6, >6–≤ 10, >10 months, missing), and Gleason score at prostate cancer diagnosis (4–7, 8–10, missing). ARI androgen receptor inhibitor, CI confidence interval, HR hazard ratio, mCRPC metastatic castration-resistant prostate cancer, MFS metastasis-free survival, nmCRPC nonmetastatic castration-resistant prostate cancer, NR not reached, PSA prostate-specific antigen. amCRPC defined by recorded evidence of metastases or use of mCRPC treatment.

Back to article page